ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
99.98
+1.01 (+1.02%)
At close: 4:00PM EDT

99.98 0.00 (0.00%)
After hours: 4:51PM EDT

Stock chart is not supported by your current browser
Previous Close98.97
Open98.82
Bid95.00 x 1000
Ask106.30 x 1000
Day's Range98.82 - 100.54
52 Week Range62.96 - 153.99
Volume485,833
Avg. Volume1,074,741
Market Cap10.05B
Beta3.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
    Market Realist12 hours ago

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.

  • What Do Alnylam’s Valuations Indicate?
    Market Realistyesterday

    What Do Alnylam’s Valuations Indicate?

    Alnylam Pharmaceuticals’ (ALNY) interest income grew from $2.1 million in Q1 2017 to $5.8 million in Q1 2018. While the company had incurred other expenses of $2.9 million in Q1 2017, it earned $335,000 in other income in Q1 2018.

  • How Has Alnylam Pharmaceuticals Performed Financially?
    Market Realistyesterday

    How Has Alnylam Pharmaceuticals Performed Financially?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) generated collaboration revenues of $21.9 million in Q1 2018 compared with $18.9 million in Q1 2017. The company earns the majority of its collaboration revenues from Sanofi Genzyme and MDCO.

  • Why Alnylam’s Clinical Pipeline Seems Promising
    Market Realistyesterday

    Why Alnylam’s Clinical Pipeline Seems Promising

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals’ (ALNY) target indications include genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. Alnylam Pharmaceuticals aims to have three products on the market and ten RNAi therapeutic clinical programs by the end of 2020.

  • Alnylam Pharmaceuticals: Banking on Strategic Collaborations
    Market Realistyesterday

    Alnylam Pharmaceuticals: Banking on Strategic Collaborations

    Alnylam Pharmaceuticals (ALNY) has formed key alliances with leading pharmaceutical and life sciences players to support its development and commercialization activities. These include Sanofi Genzyme, the specialty care global business unit of Sanofi, the Medicines Company (or MDCO), and Vir Biotechnology. Additionally, in late 2017, Alnylam Pharmaceuticals joined a research consortium with UK Biobank, Regeneron Pharmaceuticals, and four other pharmaceutical companies aimed at generating 500,000 human exome sequences linked to medical records by the end of 2019. ...

  • Exploring Alnylam Pharmaceuticals’ Clinical Programs
    Market Realistyesterday

    Exploring Alnylam Pharmaceuticals’ Clinical Programs

    Alnylam Pharmaceuticals (ALNY) presented updated phase one data for ALN-TTRsc02 in March 2018. ALN-TTRsc02 is a subcutaneously administered investigational RNAi therapeutic under development for treating ATTR amyloidosis. The drug received a positive opinion from the European Medicines Agency (or EMA) committee for orphan medicinal products for orphan drug designation in the European Union.

  • Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
    Market Realistyesterday

    Analyst Views on the Upside Potential of Alnylam Pharmaceuticals

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.

  • Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
    Motley Fool9 days ago

    Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?

    Good news for Pfizer muddies the waters somewhat for Alnylam's outlook.

  • BioMarin Begins Mid Stage Study on Gene Therapy Candidate
    Zacks9 days ago

    BioMarin Begins Mid Stage Study on Gene Therapy Candidate

    BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Looks Forward
    Motley Fool17 days ago

    Alnylam Looks Forward

    An uneventful earnings release as the company anticipates an approval of its hereditary TTR amyloidosis drug, patisiran.

  • Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
    Zacks21 days ago

    Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

    Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

  • Associated Press22 days ago

    Alnylam: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.41. Losses, adjusted for stock option expense, came to $1.22 per share. The results did not meet Wall Street expectations. ...

  • Boston biotech entrepreneur Christoph Westphal launches new startup
    American City Business Journals23 days ago

    Boston biotech entrepreneur Christoph Westphal launches new startup

    Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.

  • Dicerna Pharmaceuticals Settles All Litigation with Alnylam
    Market Realistlast month

    Dicerna Pharmaceuticals Settles All Litigation with Alnylam

    On April 20, Dicerna Pharmaceuticals (DRNA) announced that it had resolved all litigation with Alnylam Pharmaceuticals (ALNY). The settlement allows Dicerna to advance all its key and planned pipeline programs while simultaneously maintaining a strong balance sheet. Under the terms of the agreement, Alnylam will dismiss all claims of trade secret misappropriation and other related claims brought in Massachusetts against Dicerna Pharmaceuticals.

  • Motley Foollast month

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Dicerna to pay $27M to settle Alnylam trade secrets lawsuit
    American City Business Journalslast month

    Dicerna to pay $27M to settle Alnylam trade secrets lawsuit

    The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.

  • Reuterslast month

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Reuterslast month

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Alnylam (ALNY) Reports Positive Data for RNAi Candidate
    Zackslast month

    Alnylam (ALNY) Reports Positive Data for RNAi Candidate

    Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $105 million.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realistlast month

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • Why CASI Pharmaceuticals Stock Rose Last Week
    Market Realistlast month

    Why CASI Pharmaceuticals Stock Rose Last Week

    On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY